Cerulean Pharma Inc. is a clinical-stage company specializing in the development of dynamically tumor-targeted nanopharmaceuticals.

Cerulean is applying its proprietary nanopharmaceutical platform to advance a new class of therapeutic agents to address significant unmet medical needs. With an initial focus in oncology, the Company’s technology platform can be applied to a wide range of drug molecules, ranging from small molecules to peptides and RNAs. The company's most advanced product is in Phase 2 clinical trials. Cerulean was founded by MIT Professor Ram Sasisekharan, Polaris partner Alan Crane, and Harvard Professor Shiladit Sengupta.


Building companies that are based on science is all about partnerships. The people at Polaris have been some of the most special partners to me as we have founded and developed three outstanding companies in concert: Momenta, Cerulean, and Visterra. We have always been strategically aligned in our objectives to create excellent companies that can ultimately truly make a difference for patients. Towards this end the team at Polaris provides matchless, profound operational and financial experience. I look forward to embarking on many more future ventures together with them.

- Ram Sasisekharan, MIT Professor : Co-Founder, Cerulean Pharma

Contact Info

840 Memorial Drive, 5th Floor, Cambridge, MA, 02139
Tel: 617-551-9600

Polaris Lead

Alan Crane

Social Media